baber/WOPTO huggingface dataset:
Patent NZ-567511-A (NZ)
Title: Fastener with removable element
Inventor: CHUANG SHU-YUN
Filed: 2008-04-17
Abstract: A screw (4) with a removable tip section comprising a shank (41) and a tip section (42). The shank has a first threaded section (411) consisting of an upper (412a) and a lower (412b) threaded section and a recess (415) defined at the surface of an end face (414). The tip section may include a second threaded section (424) and a drilling portion (422) disposed thereon and an insertion (423) having a coincident shape with the recess. By means of the threaded sections (412a, 412b, 424) and the drilling portion (422) with different outer diameters (D1a, D1b, D2, D), the screw can be smoothly driven into metal objects (5). After screwing in, the tip section can be removed from the shank by wrench.
Patent NZ-569703-A (NZ)
Title: [quinazolin-4-yl]-(4-[1,2,4]triazol-1-ylphenyl)-amine derivatives
Inventor: CHANA SURINDER
IPC: C07D405/14
Filed: 2007-01-11
Abstract: Disclosed are [quinazolin-4-yl]-(4-[1,2,4]triazol-1-ylphenyl)-amine derivatives as represented by the general formula (I), wherein the substituents are as defined herein. Further disclosed is a pharmaceutical composition which comprises a quinazoline derivative as defined above, for use in treating or preventing a flaviviridae infection including a pestivirus infection (such as bovine viral diarrhea virus, classical swine fever virus or border disease virus), yellow fever virus, dengue fever virus, Japanese encephalitis virus or tick borne encephalitis virus. Of particular importance is the compound [6-(3,4-dimethoxy-phenyl)-quinazolin-4-yl]-(4-[1,2,4]triazol-1-ylphenyl)-amine.
Patent NZ-575870-A (NZ)
Title: Method and apparatus for extracting carbon dioxide from ambient air
Inventor: WRIGHT ALLEN B
IPC: C01B32/50
Filed: 2007-10-02
Abstract: Disclosed is a process for removing carbon dioxide from ambient air, comprising passing ambient air in contact with a sorbent to absorb carbon dioxide from the air, and delivering the absorbed carbon dioxide into a controlled environment, and collecting the absorbed carbon dioxide in the controlled environment. An apparatus when used for performing the above mentioned process is also claimed.
Patent NZ-577842-A (NZ)
Title: A concrete panel clip having a projection which prevents the clip from rotating during tightening of a fastener
Inventor: METHAM BARRY
IPC: E04B5/02
Filed: 2007-12-04
Abstract: Disclosed is a panel clip for fixing a preformed concrete panel to structural steelwork. The clip includes a linear elongate body terminating in a downward deflecting lip. The body has a punched elongate aperture suitable for receiving a fastening device. The body also has a non-load bearing projecting tooth protruding in a downward direction corresponding to the deflecting lip and formed between the end of the lip and the aperture for engaging a rebate in the preformed concrete panel. The projecting tooth prevents the clip from rotating during tightening of the fastening device whilst allowing lateral positioning of the clip during tightening.
Patent NZ-583397-A (NZ)
Title: ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
Inventor: HIRUMA YOSHIHARU
IPC: A61K31/593
Filed: 2008-10-08
Abstract: Disclosed is an antibody, or a functional fragment of the antibody, which specifically recognizes one or more polypeptides comprising an amino acid sequence described in any one of the following (a) to (i) and inhibits osteoclast formation and/or osteoclastic bone resorption: (a) an amino acid sequence represented by SEQ ID NO: 2 in the Sequence Listing; (b) an amino acid sequence consisting of amino acid residues 21 to 328 of the amino acid sequence represented by SEQ ID NO: 2 in the Sequence Listing; (c) an amino acid sequence consisting of amino acid residues 1 to 260 of the amino acid sequence represented by SEQ ID NO: 2 in the Sequence Listing; (d) an amino acid sequence consisting of amino acid residues 21 to 260 of the amino acid sequence represented by SEQ ID NO: 2 in the Sequence Listing; (e) an amino acid sequence represented by SEQ ID NO: 4 in the Sequence Listing; (f) an amino acid sequence consisting of amino acid residues 21 to 341 of the amino acid sequence represented by SEQ ID NO: 4 in the Sequence Listing; (g) an amino acid sequence consisting of amino acid residues 1 to 258 of the amino acid sequence represented by SEQ ID NO: 4 in the Sequence Listing; (h) an amino acid sequence consisting of amino acid residues 21 to 258 of the amino acid sequence represented by SEQ ID NO: 4 in the Sequence Listing; and (i) an amino acid sequence including substitution, deletion or addition of one or several amino acid residues in the amino acid sequence described in (a) to (h). Also disclosed is the use of at least one of the antibodies or functional fragments of the antibodies for the manufacture of a medicament for treating and/or preventing abnormal bone metabolism.
Patent NZ-584841-A (NZ)
Title: Nucleic acid complex and nucleic acid delivery composition
Inventor: TAKEUCHI HIROFUMI
IPC: A61K47/48
Filed: 2008-11-06
Abstract: Provided is a nucleic acid complex comprising a nucleic acid and a highly branched cyclic dextrin, wherein the highly branched cyclic dextrin is a glucan with a degree of polymerization of 50 to 5000 having an inner branched cyclic structure portion formed from alpha-1,4-glucoside bonds and at least one alpha-1,6-glucoside bond, and an outer branched structure portion bound to the inner branched cyclic structure portion. The complex can be used in the manufacture of medicaments for siRNA delivery.
Patent NZ-586093-A (NZ)
Title: wall of building with plaster applied over battens and first, second and third meshes
Inventor: OWENS DOUGLAS CHARLES
IPC: E04F13/02
Filed: 2010-06-11
Abstract: A wall of at least 2.4m high and 4m wide has studs spaced a modular distance apart. Battens are fixed on and between studs. A first mesh is applied and a second mesh is applied and supported at least in part by a plaster matrix. A further third outer mesh is applied as regional reinforcement, typically at a periphery of a door or window opening.
Patent NZ-587019-A (NZ)
Title: Capsule formulation
Inventor: UCHIYAMA YOSHIHIRO
IPC: A61K31/232
Filed: 2008-12-29
Abstract: Disclosed is a seamless capsule comprising a liquid pharmaceutically active ingredient and one or more kinds of solid pharmaceutically active ingredients, wherein the liquid pharmaceutically active ingredient is encapsulated in the form of a liquid pharmaceutical composition, and the solid pharmaceutically active ingredient is dispersed in a capsule shell layer, the liquid pharmaceutically active ingredient comprises a ù3-fatty acid ethyl ester, the ù3-fatty acid ethyl ester comprises EPA ethyl ester and DHA ethyl ester, and the liquid pharmaceutical composition comprises not less than 40 percent w/w of EPA ethyl ester and not less than 34 percent w/w of DHA ethyl ester, and the capsule shell layer is formed by a shell composition comprising glycerin and sorbitol.
Patent NZ-588185-A (NZ)
Title: Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes
Inventor: THUM THOMAS
IPC: A61K31/7105
Filed: 2009-02-26
Abstract: Disclosed is the use of a compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the modified oligonucleotide has a nucleobase sequence complementary to miR-21 or a precursor thereof, for the manufacture of a medicament for treating, preventing, or diagnosing fibrosis in a subject. Further disclosed is the use of a compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-2 1 or a precursor thereof, for the manufacture of a medicament for treating a fibroproliferative disorder. Further disclosed is an in vitro method for diagnosing fibrosis comprising the steps of: a. measuring the expression of miR-2 1 in a sample from a patient supposed to suffer from fibrosis; wherein an elevated level of miR-21 in comparison to a control sample indicates fibrosis or a predisposition thereof.
Patent NZ-588800-A (NZ)
Title: Mooring line threading boathook
Inventor: CARLSON ERIC
IPC: B63B21/04
Filed: 2008-04-11
Abstract: Disclosed is a rope or line threading device for feeding a rope through a ring member to make the tying up and securing of boats to moorings easier. The device comprises a body, a rotatable arc-shaped element connected to the body and having an opening and a line holding means arranged to slide on the arc-shaped element. The arc-shaped element is adapted to assume a first position with the opening in a first direction and a second position with the opening in a second direction. Transfer means of a beam transfers a longitudinal movement to the outer surface of the arc-shaped element in order to rotate the arc-shaped element between the first and second positions. The arc-shaped element comprises a plurality of teeth on the outer surface that act as the transfer means.
Patent NZ-589852-A (NZ)
Title: Dentures, dental arches and methods of manufacture
Inventor: RIGGIO SEBASTIAN
IPC: A61C13/01
Filed: 2009-06-11
Abstract: 589852 Disclosed is a rigid support (10) of a dental arch of a denture. The invention to seeks to reduce the time taken to produce dentures and/or improve the quality of the dentures produced and/or the method of production of dentures. The support has a rigid elongate member (12) curved to substantially follow a curve of a dental arch wherein an anterior region (16) of the elongate member morphs or twists into the posterior regions (20) of the elongate member approximately at post-cuspid regions, flattening towards a more horizontal formation (18) from second bicuspid regions to molar regions.
Patent NZ-590034-A (NZ)
Title: Process for preparing a crumb coating comprising the milling of a heated and extruded flour mixture
Inventor: PICKFORD KEITH GRAHAM
IPC: A23L7/157
Filed: 2009-06-30
Abstract: Disclosed is a process of manufacture of a crumb coated food product comprising the steps of forming an aqueous mixture comprising: i. a flour mixture comprising one or more flours, ii. sodium bicarbonate, iii. optional additives selected from processing aids, salts, colourants and, iv. water; v. adding the mixture into an extruder; vi. adding an aqueous gelling agent to the extruder; vii. extruding the resultant mixture at a temperature greater than 100 degrees C to form an extrudate; viii. allowing the extrudate to expand to form a porous product; ix. drying the product, and x. milling the dried product to form a crumb.
Patent NZ-592267-A (NZ)
Title: Methods and apparatus for reducing protein content in sperm cell extenders
Inventor: SCHENK JOHN L
IPC: C12N5/076
Filed: 2006-07-24
Abstract: Disclosed is a method for processing sorted sperm cells compromised by a sorting event comprising the steps of:   subjecting a plurality of sperm cells to sorting stresses;   selecting said plurality of sperm cells for a desired characteristic;   providing a protein-free sperm cell extender;   providing a protein-free cryoprotectant-containing sperm cell extender;   combining said protein-free sperm cell extender and said protein-free cryoprotectant-containing sperm cell extender to form a cryoprotectant- containing centrifugation medium;   maintaining said cryoprotectant-containing centrifugation medium in an unclarified state;   adding said plurality of sperm cells subjected to soiling stresses and selected for a desired characteristic to said unclarified cryoprotectant- containing centrifugation medium to form an unclarified cryoprotectant- containing sperm cell centrifugation medium;   subjecting said unclarified cryoprotectant-containing sperm cell centrifugation medium to centrifugation; and   decanting a portion of said centrifuged unclarified cryoprotectant- containing sperm cell centrifugation medium.
Patent NZ-596674-A (NZ)
Title: Use of pufas to treat nerve damage
Inventor: KELLIHER ADAM
IPC: A61K31/202
Filed: 2010-04-22
Abstract: 596674 Disclosed herein is a compound of formula (I), wherein the variables are defined in the specification, and the use thereof for preventing a diabetic neuropathy, such as dizziness, indigestion, bladder infections, foot sores, wastage of thigh muscles, sexual dysfunction, numbness, burning sensations, pain, tingling in the legs and feet, decreased temperature perception, decreased ankle reflex and/or decreased sensitivity to vibrations.
Patent NZ-596748-A (NZ)
Title: Rope descender with self- acting brake
Inventor: ROGELJA BORIS
IPC: A62B1/14
Filed: 2010-06-09
Abstract: A descender (5) for use in abseiling or belaying, comprising a base (10) connected to a harness or the like, with first (16) and second (18) spaced projections engaging a rope, the projections (16, 18) both extending normal to the base (10); an arm (12) pivotally mounted to the base (10) at a pivot axis (14), the arm (12) having a third projection (28) for engaging a rope, the projection (28) extending parallel to the pivot axis (14) and being located so that when the arm (12) is pivoted towards the base (10), the third projection (28) is located between the first (16) and second (18) spaced projections, wherein a fourth projection (156) disposed generally between the first (16) and second (18) projections and adjacent an edge of the base (10) separates a portion of rope passing into the descender (5) and around the first (16) and third (18) projections from the portion of the same rope passing out of the descender (5) between the third (28) and second (18) projections.
Patent NZ-601672-A (NZ)
Title: A sound attenuation stud
Inventor: BEAN STEPHEN CHARLES
IPC: E04B1/84
Filed: 2011-03-15
Abstract: 601672 A sound attenuation stud (2). The stud includes two engagement portions (4a, 4b) for engaging within a building element. The stud also includes two sound attenuation formations (8a, 8b). Each sound attenuation formation includes a first portion (10a, 10b) relative to which second and third portions (12, 14) extend. The second and third portions are less than half the length of the engagement portions. Preferably, the sound attenuation formations are located between the engagement portions. Preferably, each portion is either parallel or orthogonal with all the other portions.
Patent NZ-602416-A (NZ)
Title: Optically-based stimulation of target cells and modifications thereto
Inventor: DEISSEROTH KARL
IPC: C07K14/00
Filed: 2009-09-13
Abstract: Discloses an isolated cell comprising a nucleic acid encoding a light responsive ion channel comprising an amino acid sequence having at least 90% amino acid sequence identity SEQ ID NO: 1 or SEQ ID NO: 2, wherein the sequences comprise: (i) a substitution of a Cys residue at residue 128 (C128) and a substitution an Asp residue at amino acid residue 156 (D156) of SEQ ID NO:1, or (ii) a substitution of Cys residue at residue 123 (C123) and a substitution an Asp residue at amino acid residue 151 (D151) of SEQ ID NO:2; such that the light-responsive ion channel exhibits an extended conducting or non-conducting state after exposure to a light pulse of 10 ms or less.
Patent NZ-602730-A (NZ)
Title: Topical pharmaceutical compositions comprising mometasone furoate
Inventor: WILLERS CHRISTOPH
IPC: A61K9/06
Filed: 2011-05-13
Abstract: NZ 602730 The disclosure relates to topical pharmaceutical compositions comprising, based on the total weight of the composition: (a) 0.01 to 0.2 wt.% of mometasone furoate, (b) 5 to 18 wt.% of hexylene glycol, (c) 20 to 40 wt.% of water, and (d) 25 to 70 wt.% of an oil phase, wherein the mometasone furoate is suspended (dispersed) in the composition. Said compositions are stable and can be safely and easily applied over large surface areas of the skin in an acceptable way by the general patient population for the treatment or prevention of psoriasis, atopic dermatitis (atopic eczema) and other skin disorders or diseases.
Patent NZ-602905-A (NZ)
Title: Fgf-r4 receptor-specific antagonists
Inventor: BAURIN NICOLAS
IPC: A61K39/395
Filed: 2009-07-07
Abstract: 602905 Disclosed is the use of a FGF-R4 antagonist antibody which comprises CDRs of sequence SEQ ID Nos. 9 (TSGMGVS), 10 (HIYWDDDKRYNPSLKS), 11 (DYYASSFDY), 12 (RASQSISNYLH), 13 (YASQSIS) and 14 (QQSNSWPFT), where each one of the CDRs may differ by one or two amino acids compared with its respective sequence mentioned above, provided that the antibody keeps its binding specificity for FGF-R4, in the manufacture of a medicament to treata disease related to a pathological angiogenesis.
Patent NZ-614600-A (NZ)
Title: Probe for analyzing biological tissue and method for utilizing same
Inventor: YAMAGATA YOUHEI
IPC: G01N33/53
Filed: 2012-03-15
Abstract: Disclosed is a method for analysing a biological tissue, comprising applying two or more probes respectively containing collagen binding domains of two or more proteases to an isolated biological tissue, and analysing binding amounts of the probes to the biological tissue.
Patent NZ-615845-A (NZ)
Title: Air spring counterbalance
Inventor: BRIAN ROY SKOTTY
IPC: F16F9/04
Filed: 2013-09-24
Abstract: Disclosed is a system for moving a movable barrier, such as a garage door (see figure 11). The system comprises a fluid-based spring counterbalance mechanism (100) coupled via at least one rotatable shaft (180) to the movable barrier. The fluid-based spring counterbalance mechanism comprises a flexible fluid-based gas, or air, spring (110) held between upper and lower plates (120, 130). A translational mechanism (150), coupled to the rotating shaft, is configured to compress the air spring between the two surfaces in response to rotation of the rotatable shaft, such that potential energy is stored in the loaded compressed air spring. The counterbalance mechanism utilises this stored potential energy to support at least a portion of the movable barrier’s weight during movement, such as opening or closing, of the movable barrier. The translational mechanism includes a cable (150) fixed at one end (151) to the upper plate and then passing over a pulley (160) on the lower plate, with its other end fastened around a drum (170) located above the top plate, which is driven by the rotating shaft. Rotation of the rotating shaft causes the drum to draw in the cable, thereby compressing the air spring. A method of installing the fluid-based counterbalance mechanism and a method of controlling a position of a movable barrier are also disclosed. Both methods include adjusting the tension of the flexible fluid-based spring by controlling the amount of air, or fluid, held in the flexible fluid-based spring.
Patent NZ-619248-A (NZ)
Title: Methods and assemblies for welding a gasket to a pipe section
Inventor: BABCANEC JOSEPH A
IPC: F16L21/035
Filed: 2013-12-19
Abstract: A gasket (20) for providing a seal between a bell portion of a first corrugated pipe section and a spigot portion of a second corrugated pipe section, the gasket comprising: a seating portion (26) extending radially and dimensioned to fit within an annular recess in the spigot portion; and a sealing portion (30) including a first shoulder (32) portion axially extending from one side of the seating portion and a second shoulder portion (34) extending from the other side of the seating portion. The first and second shoulder portions are configured to engage the spigot portion on axially opposite sides. A first bonding portion (42) extends from the first shoulder portion and a second bonding portion (44) extends from the second shoulder portion. The first bonding portion and the second bonding portion are configured to bond the gasket to the spigot portion. A notch (40) is formed in the second shoulder portion.
Patent NZ-620582-A (NZ)
Title: Current regulator
Inventor: BANNISTER DAVE
IPC: G05F3/18
Filed: 2012-06-22
Abstract: The present application describes a current regulator for providing a regulated current from an input voltage. The current regulator comprises a voltage regulator circuit, operable to provide a regulated voltage, which comprises a plurality of Zener diodes of nominally the same Zener voltage connected in parallel. Each Zener diode has a Zener voltage of less that 5.5V and the Zener diodes are selected such that a variation of between 0.1V and 0.3V exists between their Zener voltages.
Patent NZ-708137-A (NZ)
Title: Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
Inventor: ALLEN SHELLEY
IPC: A61P25/00
Filed: 2013-11-13
Abstract: Disclosed are compounds of Formula I, or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein Ring A is of formula A-1, where B is NR1 and D is CRfRg; or B is CRdRe and D is NR1; E is a bond; F is CRjRk; X is O; and ring C is a substituted pyrazole of formula C-1 and wherein the remaining variables are as defined herein. The compounds are provided as inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren’s syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
Patent NZ-710745-A (NZ)
Title: Pyrrolobenzodiazepines and conjugates thereof
Inventor: FLYGARE JOHN
IPC: A61K31/5517
Filed: 2014-03-13
Abstract: The present invention relates to pyrrolobenzodiazepines (PBDs), in particular pyrrolobenzodiazepines having a linker group connected to a cell binding agent. In one aspect, the present invention provides a conjugate comprising a PBD dimer connected through the dimer bridging portion via a specified linker to a cell binding agent. The present invention is suitable for use in providing a PBD conjugate to a preferred site in a subject. In particular, the present invention provides a conjugate of formula (A), use of a conjugate of formula (A) the manufacture of a medicament, a pharmaceutical composition comprising a conjugate of formula (A), a compound of formula (B), a compound of formula (C), a compound of formula (D), a compound of formula (E) and/or a method of synthesis of a compound. In preferred embodiments, use of a conjugate of formula (A) the manufacture of a medicament for treating cancer and/or a proliferative disease. Conjugate compounds of formula (A): wherein: R2 is, where R36a and R36b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester; or, when one of R36a and R36b is H, the other is selected from nitrile and a C1-4 alkyl ester; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR’, NO2, Me3Sn and halo; R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR’, NO2, Me3Sn and halo; Y is selected from formulae A1, A2, A3, A4, A5 and A6: L is a linker connected to a cell binding agent; CBA is the cell binding agent; n is an integer selected in the range of 0 to 48; RA4 is a C1-6 alkylene group; either (a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl; or (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is OSOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; R and R’ are each independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups, and optionally in relation to the group NRR’, R and R’ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; wherein R16, R17, R19, R20, R21 and R22 are as defined for R6, R7, R9, R10, R11 and R2 respectively; wherein Z is CH or N; wherein T and T’ are independently selected from a single bond or a C1-9 alkylene, which chain may be interrupted by one or more heteroatoms e.g. O, S, N(H), NMe, provided that the number of atoms in the shortest chain of atoms between X and X’ is 3 to 12 atoms; and X and X’ are independently selected from O, S and N(H).